Ilaria Marcon
Research Subjects
Research Interests
Ilaria Marcon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
1 shared publication - Carlo Carnaghi
Humanitas Cancer Center–Istituto Clinico Humanitas, Istituto Di Ricovero e Cura a Carattere Scientifico, Rozzano, Italy
1 shared publication - Emanuela Morenghi
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy
1 shared publication - Giovanni Abbadessa
ArQule Inc., Burlington, MA 01803, USA
1 shared publication - Giuseppe Gullo
St Vincent's University Hospital, Dublin 4, Ireland
1 shared publication - Isabella Garassino
Department of Oncology and Hematology, Istituto Clinico Humanitas IRCCS, 20089 Rozzano (Milano), Italy
1 shared publication
Latest Publications
- 11 May 2007
- Published by Springer Nature in Investigational New Drugs
- Vol. 25 (5) , 479-485
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study
Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2–63) and the median overall survival (OS) 21 months (range 6–63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.
- 11 May 2007
- Published by Springer Nature in Investigational New Drugs
- Vol. 25 (5) , 479-485
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study
Intra-arterial chemotherapy in patients with liver metastases from colorectal cancer has some limitations such as hepatic toxicity and extra-hepatic progression. With the aim of overcoming these limitations, a phase II trial was designed to assess the efficacy and tolerability of a hybrid chemotherapy regimen with systemic infusion of oxaliplatin and folinic acid associated with intra-arterial 5-fluorouracil. Thirty-nine patients with colorectal liver metastases were recruited. The median age was 59 years, 30 patients (77%) had synchronous metastases, and half of the patients were chemo-naive. A total of 313 chemotherapy cycles were administered (median number 8). Treatment was well tolerated and hepatic toxicity negligible. Out of 34 evaluable patients an ORR of 41%. was observed. Eight patients (21%) underwent radical liver surgery. The median time to progression (TTP) was 10 months (range 2–63) and the median overall survival (OS) 21 months (range 6–63). Extra-hepatic progression was observed in six patients. Our results suggest that this regimen is active even if technical complications are frequent. Our aim to reduce hepatic toxicity and extra-hepatic progression was reached.